Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Replimune Group, Inc. (Nasdaq: REPL) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a clinical stage biotechnology issuer. Replimune, founded in 2015 and headquartered in Woburn, Massachusetts, develops HSV‑1‑based oncolytic immunotherapies through its proprietary RPx platform, with lead programs such as RP1 (vusolimogene oderparepvec) and RP2.
Through this page, users can review Replimune’s current reports on Form 8‑K, which frequently highlight material events including FDA interactions, clinical milestones and financial updates. Recent 8‑K filings have described the FDA’s Complete Response Letter for the RP1 BLA in advanced melanoma, completion of a Type A meeting with the agency, acceptance of a BLA resubmission with a defined PDUFA date, quarterly financial results, and outcomes of the company’s annual meeting of stockholders.
In addition to 8‑Ks, investors can reference Replimune’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (accessible via the SEC’s EDGAR system) for detailed information on the company’s clinical programs, risk factors, financial condition and cash runway assumptions. The DEF 14A proxy statement provides insight into governance, board structure, executive compensation and matters submitted to shareholder vote, such as director elections and incentive plan amendments.
Stock Titan enhances these filings with AI‑powered summaries that explain the key points of lengthy documents, helping users quickly understand topics like trial design disclosures, regulatory status updates for RP1 and RP2, and the implications of shareholder meeting results. Real‑time updates from EDGAR mean that new Replimune filings, including future 10‑K, 10‑Q, 8‑K and proxy materials, are made available promptly.
For those monitoring insider and equity‑related activity, Replimune’s filings also describe equity incentive plans and inducement grants under Nasdaq Listing Rule 5635(c)(4). Form 4 insider transaction reports, when filed, can be viewed alongside these materials to provide additional context on equity ownership and changes over time.
Replimune Group, Inc. filed an 8-K reporting stockholder voting results and a regulatory update. Stockholders cast tens of millions of votes for multiple director nominees, with each nominee receiving substantially more votes "for" than "withheld," such as Michael Goller with 62,116,691 votes for and 371,431 withheld.
The filing also lists vote counts on additional matters, including one item with 70,375,492 votes for and 142,326 against, and another with 61,212,356 votes for and 1,250,054 against. Separately, the company disclosed that a Type A meeting with the U.S. Food and Drug Administration has been scheduled, as announced in a news release furnished as Exhibit 99.1.
Emily Luisa Hill, Chief Financial Officer of Replimune Group, Inc. (REPL), reported the disposition of common stock on 08/15/2025. The filing shows 9,154 shares were sold at $5.37 per share to satisfy tax withholding associated with partial vesting of restricted stock units. After the sale, the reporting person beneficially owned 134,368 shares. The Form 4 notes the sale was executed under the award agreement's irrevocable "sell to cover" provision and was not a discretionary sale by the reporting person. The form was signed by an attorney-in-fact on 08/19/2025.
On 21-Jul-2025 Replimune Group, Inc. (REPL) received a Complete Response Letter (CRL) from the U.S. FDA for its Biologics License Application seeking approval of oncolytic immunotherapy RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The CRL means the agency will not approve the application in its current form and requires additional information before reconsideration. Specific deficiencies and next steps were not disclosed in the 8-K.
The company furnished, but did not “file,” a news release (Exhibit 99.1) under Item 7.01/8.01. No financial statements, earnings impact, or updated guidance were provided. The setback could delay potential commercialization and future revenue for RP1, increasing regulatory uncertainty and development costs.
FAQ
What is the current stock price of Replimune Group (REPL)?
What is the market cap of Replimune Group (REPL)?
